The Opportunity in Myeloma Target Antigens
Beyond BCMA, research is actively exploring other target antigens for multiple myeloma in the CAR T Cell Therapy Market. While BCMA has been the most successful target to date, the possibility of patients relapsing due to a loss of BCMA expression has led researchers to investigate new targets and dual-targeting approaches. Antigens like GPRC5D and FcRH5 are being explored as potential targets, either as a standalone therapy or in combination with BCMA-targeted CAR T-cells. This focus on new targets is a clear indicator of the market's continued innovation and its commitment to overcoming the challenges of treatment resistance.
The market for new myeloma target antigens is being driven by the need to improve long-term outcomes and to find effective treatments for patients who have relapsed after BCMA-targeted therapy. As more clinical trials demonstrate the efficacy of these new targets, they are expected to be a key driver of market growth and a new opportunity for market players.